CCDC6 and non-small cell lung carcinoma: The most prevalent fusion partners in NSCLC were KIF5B (72.9%, 51/70) and CCDC6 (17.1%, 12/70), while NCOA4 (42.9%, 3/7) and CCDC6 (28.6%, 2/7) were dominant in PTC.